Status:

COMPLETED

Mind Body Intervention for COVID-19 Long Haul Syndrome

Lead Sponsor:

Beth Israel Deaconess Medical Center

Conditions:

COVID-19 Long Haul Syndrome

Eligibility:

All Genders

18-60 years

Phase:

NA

Brief Summary

The present study is a feasibility study in which we will determine if a mind-body program that we have previously developed for chronic back pain can improve the multiple somatic complaints associate...

Detailed Description

This study is a pilot and feasibility study to determine if a mind-body program that we have previously developed for chronic back pain can improve the multiple somatic complaints associated with the ...

Eligibility Criteria

Inclusion

  • Adult patient ≥ 18 years old
  • New symptoms attributed to the post-covid long-haul syndrome (extremity pain, dyspnea, headaches, chest pain, fatigue) occurring after an acute phase of COVID19
  • Minimum of at least 12 weeks after the end of the acute phase of COVID-19 infection
  • Persistence of symptoms for a least 1 month with no identified other organic etiology
  • Score ≥ 3 or more on the SSS-8 score
  • Symptoms present for a minimum of 4 days a week
  • Willingness to consider mind-body intervention

Exclusion

  • Patients \< 18 years of age
  • Patients \> 60 years of age
  • Diagnosed (non-COVID-19) organic disease as cause of pain, such as (but not limited) to malignancy, neurologic disorder (i.e., amyotrophic lateral sclerosis), cauda equina syndrome (note that pain related to disc disease is not an exclusion unless there are neurological impairments).
  • Patients with previous severe COVID-19 disease, defined as those who had been admitted to the ICU or have objective evidence of ongoing organ injury (e.g., persistent chest radiographic abnormalities or myocarditis)
  • Identified lung or cardiac injury in subjects with chest pain or dyspnea (e.g., chest radiograph abnormalities, cardiac ultrasound showing myocarditis or depressed ejection fraction )
  • Patients with a diagnosis of significant psychiatric comorbidities such as schizophrenia or dementia

Key Trial Info

Start Date :

May 15 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 9 2022

Estimated Enrollment :

23 Patients enrolled

Trial Details

Trial ID

NCT04854772

Start Date

May 15 2021

End Date

August 9 2022

Last Update

August 19 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States, 02215